Tranquility Partners LLC Sells 305 Shares of Zoetis Inc. (NYSE:ZTS)

Tranquility Partners LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,698 shares of the company’s stock after selling 305 shares during the quarter. Tranquility Partners LLC’s holdings in Zoetis were worth $1,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in shares of Zoetis by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after buying an additional 297,044 shares during the period. Morgan Stanley lifted its holdings in shares of Zoetis by 34.6% during the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after buying an additional 2,796,694 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Zoetis by 0.3% during the 1st quarter. Geode Capital Management LLC now owns 9,739,370 shares of the company’s stock valued at $1,617,464,000 after buying an additional 27,097 shares during the period. Northern Trust Corp lifted its holdings in shares of Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after buying an additional 196,771 shares during the period. Finally, Norges Bank bought a new position in shares of Zoetis during the 4th quarter valued at $745,861,000. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday. The Goldman Sachs Group raised their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $230.00 target price on shares of Zoetis in a report on Tuesday, December 19th. Barclays raised their target price on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $221.75.

Zoetis Price Performance

ZTS stock traded down $1.08 during trading on Wednesday, reaching $151.94. The company’s stock had a trading volume of 3,258,747 shares, compared to its average volume of 2,965,319. Zoetis Inc. has a 1 year low of $148.48 and a 1 year high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $69.49 billion, a P/E ratio of 30.18, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company’s fifty day moving average is $178.25 and its 200-day moving average is $180.59.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the previous year, the company posted $1.15 EPS. The company’s quarterly revenue was up 8.5% on a year-over-year basis. On average, research analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.14%. Zoetis’s payout ratio is 34.12%.

Insider Activity

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now owns 20,417 shares in the company, valued at $4,037,257.58. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 2,209 shares of company stock worth $408,453 over the last 90 days. Corporate insiders own 0.15% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.